Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Authors:
Open Access
- 1 April 2021
- journal article
- review article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 27 (2) , 221-235
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.Keywords
This publication has 142 references indexed in Scilit:
- Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trialsBMJ, 2013
- Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysisBiomedical Reports, 2012
- 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: A therapeutic controversyJournal of Clinical Lipidology, 2011
- Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjectsHepatology, 2011
- Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic SteatohepatitisClinical Journal of the American Society of Nephrology, 2010
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASHJournal of Gastroenterology, 2010
- Apnoeic–hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitisLiver International, 2008
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003